Javascript must be enabled to continue!
The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
View through CrossRef
Abstract
Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant
p
-value group (
p
-values < 0.001). Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47 ± 4.43, 28.01 ± 3.75, 29.64 ± 3.90) were lower than healthy group (34.23 ± 3.54, 32.90 ± 4.15, 32.18 ± 5.02) (
p
-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.9%, sensitivity of 77.6% and specificity of 75%. Also, we founded that our gene combination performs better than the current gold standard for HCC screening. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods.
Springer Science and Business Media LLC
Title: The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
Description:
Abstract
Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC).
Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method.
The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs.
Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected.
As a result, GSE 49515 and GSE 58208 were found.
Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes.
We randomized three selected genes (FLNA, CAP1, and CLU) from the significant
p
-value group (
p
-values < 0.
001).
Then, a total of 76 healthy donors, 153 HCC, 20 hepatic fibrosis, 20 non-alcoholic fatty liver were collected.
Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samples from the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.
47 ± 4.
43, 28.
01 ± 3.
75, 29.
64 ± 3.
90) were lower than healthy group (34.
23 ± 3.
54, 32.
90 ± 4.
15, 32.
18 ± 5.
02) (
p
-values < 0.
0001).
The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.
8%, 88.
0%, 65.
8%), CLU (63.
4%, 93.
3%, 31.
3%), CAP1 (67.
2%, 83.
3%, 39.
1%).
The tests were performed in two and three gene combinations.
Results demonstrated high accuracy of 86.
2%, sensitivity of 85% and specificity of 88.
4% in the FLNA and CLU combination.
Furthermore, after analyzed using hepatic fibrosis and non-alcoholic fatty liver as a control, the FLNA and CLU combination is shown to have accuracy of 76.
9%, sensitivity of 77.
6% and specificity of 75%.
Also, we founded that our gene combination performs better than the current gold standard for HCC screening.
We concluded that FLNA and CLU combination have high potential for being HCC novel markers.
Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
The Expression of FLNA and CLU in PBMCs As A Novel Screening Marker for Hepatocellular Carcinoma.
The Expression of FLNA and CLU in PBMCs As A Novel Screening Marker for Hepatocellular Carcinoma.
Abstract
Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an i...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Teores foliares de macronutrientes em crisântemos cultivados em substratos contendo composto de lixo urbano e casca de arroz carbonizada.
Teores foliares de macronutrientes em crisântemos cultivados em substratos contendo composto de lixo urbano e casca de arroz carbonizada.
O objetivo deste trabalho foi investigar a influência da adição de composto de lixo urbano (CLU) e de casca de arroz carbonizada (CAC) no crescimento e nos teores foliares de macro...
Evaluating the GALAD Score in Diagnosing Hepatocellular Carcinoma
Evaluating the GALAD Score in Diagnosing Hepatocellular Carcinoma
This paper aims to evaluate the GALAD score in diagnosing hepatocellular carcinoma. The paper conducted a retrospective study of 86 Hepatocellular Carcinoma patients who underwent ...
The clusterin paradigm in prostate and breast carcinogenesis
The clusterin paradigm in prostate and breast carcinogenesis
The biological functions of clusterin (CLU, also known as ApoJ, SGP2, TRPM-2, CLI) have been puzzling the researchers since its first discovery in the early 80's. We know that CLU ...
Link of BIN1, CLU, and fIDE Gene Polymorphisms with the Susceptibility
of Alzheimer’s Disease: Evidence from a Meta-analysis
Link of BIN1, CLU, and fIDE Gene Polymorphisms with the Susceptibility
of Alzheimer’s Disease: Evidence from a Meta-analysis
Background:
Alzheimer’s disease (AD) is the most common form of neurodegenerative disorder.
The association of BIN1, CLU, and IDE genetic polymorphisms with AD risk have been evalu...
Abstract 1592: CXCR4 pathways in CTCs: from bioinformatics to immunophenotype
Abstract 1592: CXCR4 pathways in CTCs: from bioinformatics to immunophenotype
Abstract
Introduction: Bioinformatics’ analysis regarding gene expression in Normal tissue vs cancer tissue, Normal blood vs cancer patients’ blood and Normal blood ...

